Amarin Corp Plc (AMRN)

[Insync_2000]

$4.50 a share. Really ??? at 1.6 billion BP will be lined up 3 deep and 6 wide to get at Amarin. Hell, Europe alone is worth $15 a share or $6 billion. Further, Vascepa is not aggressively priced which means the generics are unlikely to profit from moving into this space, especially given that Amarin has supply tied up. As a worse case, Amarin may have to compete at generic pricing in the US, while the rest of the world is ripe for the taking with Europe approval being less than a year away.

This is a time to be buying, not running with your tail between your legs.